Working... Menu

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00210002
Recruitment Status : Terminated
First Posted : September 21, 2005
Last Update Posted : November 14, 2006
Information provided by:
Institut Claudius Regaud

Brief Summary:
The purpose of this study is to evaluate the response rate obtained in an heterogeneous oncologic population treated by chemotherapy, and either by Darbepoetin alfa classic treatment or by association of Darbepoetin alfa -ferric saccharose systematic supplementation, administered concomitantly with chemotherapy.

Condition or disease Intervention/treatment Phase
Neoplasms Anemia Drug: Darbepoetin alfa (Aranesp®) Drug: Ferric saccharose(Venofer®) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Evaluation of Systematic Intravenous Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced.
Study Start Date : November 2003
Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia Iron

Primary Outcome Measures :
  1. Biological response rate for each group.

Secondary Outcome Measures :
  1. To determine tolerance for ferric saccharose (Venofer®)
  2. To determine percentage of patients who necessitate an increase of Darbepoetin alfa's dose(Aranesp®)
  3. To determine percentage of hemoglobin rate's correction
  4. To determine biological parameters's evolution

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years
  • Well-informed written consent, signed by the patient
  • Patient picked up for solid tumor treatment, whichever the localization, with or without metastasis
  • Patient revealing, before or during chemotherapy, a moderate anemia, that means: Men: 9<Hb<12 g/dl; Women: 9<Hb<11 g/dl.
  • Patient for who at least four chemotherapy cycles are planed (eight in case of weekly chemotherapy) after inclusion in the study
  • Patients with life expectancy higher than three months
  • Patient with general conditions compatible with the study's follow-up

Exclusion Criteria:

  • Contra-indication for Venofer
  • Anemia which can have curative treatment
  • Bloody transfusion during the previous four weeks
  • Documented or suspected medullary invasion
  • Uncontrolled arterial hypertension
  • Acute bacterial infection
  • Transferrin saturation's coefficient
  • Pregnancy
  • Ferric salts oral treatment interrupted since less than one week
  • Patient with bad french language's comprehension
  • Patient with a major psychiatric pathology
  • Patient under guardianship, trusteeship or justice safeguard

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00210002

Layout table for location information
Centre Hospitalier de Castres
Castres, France
Centre Hospitalier de Montauban
Montauban, France
Centre Hospitalier Joseph Ducuing
Toulouse, France
Institut Claudius Regaud
Toulouse, France
Sponsors and Collaborators
Institut Claudius Regaud
Layout table for investigator information
Principal Investigator: Roland Dugat, Pr Institut Claudius Regaud

Layout table for additonal information Identifier: NCT00210002     History of Changes
Other Study ID Numbers: 03 DIVE 01
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: November 14, 2006
Last Verified: November 2006

Keywords provided by Institut Claudius Regaud:
darbepoetin alfa
ferric saccharose

Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Diseases
Darbepoetin alfa
Ferric Oxide, Saccharated